. Author manuscript; available in PMC: 2018 Apr 12.

Published in final edited form as: Am J Obstet Gynecol. 2017 May 15;217(3):369.e1–369.e9. doi: 10.1016/j.ajog.2017.05.019

TABLE 1.

Single nucleotide polymorphisms of selected genes included in analysis

Allele variant	Reference SNP identification no.	Substitution	Functionality
CYP3A4*22	rs35599367	C>T	Decreased enzymatic activity^9–17
CYP3A4*1B	rs2740574	A>G	Higher enzymatic expression in vitro,²⁰ however in vivo studies suggest reduced catalytic activity for this allele²¹
CYP3A4*1G	rs2242480	C>T	Gain-in-function polymorphism that increases enzymatic activity^18,19
CYP3A5*3	rs776746	A>G	Decreased enzymatic activity^9–17
PR SNP	rs578029	A>T	May affect clinical efficacy of 17OHP-C³³
PR SNP	rs471767	A>G	May affect clinical efficacy of 17OHP-C³³
PR SNP	rs666553	C>T	May affect clinical efficacy of 17OHP-C³³
PR SNP	rs503362	C>G	May affect clinical efficacy of 17OHP-C³³
PR SNP	rs500760	A>G	May affect clinical efficacy of 17OHP-C³³
PR SNP	rs653752	C>G	May affect clinical efficacy of 17OHP-C³³

PR, progesterone receptor; SNP, single nucleotide polymorphism; 17 OHP-C, 17-alpha hydroxyprogesterone caproate.

Bustos et al. Association of CYP3A and PR SNPs and 17 OHP-C. Am J Obstet Gynecol 2017.